Reynald Castaneda

Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test by year’s end.

Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase …

Eli Lilly, which has made billions off of the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront in a global pact for a GLP-2 analog called sonefpeglutide. The Seoul-based biotech could receive up to $1.185 billion in R&D, regulatory and sales milestone payments, on top of potential royalties.

Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered 'landmark' results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy events that call this into question.

ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial.

Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.

Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with up to $1.8B in milestones.

Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in psychedelics.

Deputy Editor Celldex said on Tuesday it will stop investigating its mast cell-targeting monoclonal antibody in a type of chronic itch disease after it failed on all …

Deputy Editor Ipsen has its eyes trained on more M&A — and has €2 billion worth of “firepower” to do it, based on its cash position at the …